Scholarlink

Background <p><i>KRAS</i> mosaic activating variants are the main cause of non-ossifying fibromas (NOFs), the most common benign lesion of the growing skeleton. Multifocal NOFs cause bone fragility, and no specific treatment is currently available.</p> Methods <p>We report two children, carrying mosaic <i>KRAS</i> variants (p.G13D and p.A146T), presenting with oculoectodermal syndrome and recurrent fractures due to progressive polyostotic NOFs. To assess the impact of these mutations on KRAS function, we conducted transient KRAS overexpression in HEK293 cells and then tested the effect of the MEK-inhibitor trametinib at the cellular level.</p> Results <p>We show that trametinib yields, in vitro, significant reduction of RAS-pathway hyperactivation induced by the two <i>KRAS</i> variants and, in vivo, remarkable clinical and radiological improvement with no recurrence of fractures and reossification of NOFs under treatment; resurgence of lesions is observed one year after stopping treatment.</p> Conclusions <p>Hence, trametinib constitutes a promising precision therapeutic approach for severe <i>KRAS</i>-related NOFs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Trametinib for multiple non-ossifying fibromas due to KRAS mosaic mutations: two case reports

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Marie Vincent,
  • Soizic Tiriau,
  • Marine Fouillet-Desjonqueres,
  • Alicia Besson,
  • Wassim Ouchetto,
  • Sébastien Barbarot,
  • Bertrand Isidor,
  • Aymeric Rouchaud,
  • Geneviève Baujat,
  • Pierre Vabres,
  • Patrick Edery,
  • Marion Delous,
  • Massimiliano Rossi

摘要

Background

KRAS mosaic activating variants are the main cause of non-ossifying fibromas (NOFs), the most common benign lesion of the growing skeleton. Multifocal NOFs cause bone fragility, and no specific treatment is currently available.

Methods

We report two children, carrying mosaic KRAS variants (p.G13D and p.A146T), presenting with oculoectodermal syndrome and recurrent fractures due to progressive polyostotic NOFs. To assess the impact of these mutations on KRAS function, we conducted transient KRAS overexpression in HEK293 cells and then tested the effect of the MEK-inhibitor trametinib at the cellular level.

Results

We show that trametinib yields, in vitro, significant reduction of RAS-pathway hyperactivation induced by the two KRAS variants and, in vivo, remarkable clinical and radiological improvement with no recurrence of fractures and reossification of NOFs under treatment; resurgence of lesions is observed one year after stopping treatment.

Conclusions

Hence, trametinib constitutes a promising precision therapeutic approach for severe KRAS-related NOFs.